Altimmune, Inc.
ALT
$5.61
-$0.36-6.03%
| Weiss Ratings | ALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 2.01 | |||
| Price History | ALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.72% | |||
| 30-Day Total Return | -12.89% | |||
| 60-Day Total Return | -33.21% | |||
| 90-Day Total Return | -17.38% | |||
| Year to Date Total Return | -21.10% | |||
| 1-Year Total Return | -38.22% | |||
| 2-Year Total Return | -48.63% | |||
| 3-Year Total Return | -22.19% | |||
| 5-Year Total Return | 98.94% | |||
| 52-Week High % Change | -46.51% | |||
| 52-Week Low % Change | 16.15% | |||
| Price | ALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $11.16 | |||
| 52-Week Low Price | $5.14 | |||
| 52-Week Low Price (Date) | Mar 13, 2025 | |||
| 52-Week High Price (Date) | Nov 13, 2024 | |||
| Valuation | ALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 459.77M | |||
| Enterprise Value | 329.56M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.34 | |||
| Earnings Per Share Growth | -18.58% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 29,850.00 | |||
| Price/Book (Q) | 3.50 | |||
| Enterprise Value/Revenue (TTM) | 16,478.08 | |||
| Price | $5.61 | |||
| Enterprise Value/EBITDA (TTM) | -3.20 | |||
| Enterprise Value/EBIT | -3.19 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | ALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 71.26M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 240 654 1450 | |||
| Address | 910 Clopper Road Gaithersburg, MD 20878 | |||
| Website | altimmune.com | |||
| Country | United States | |||
| Year Founded | 1997 | |||
| Profitability | ALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -515,860.00% | |||
| Profit Margin | -475,295.00% | |||
| Management Effectiveness | ALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -36.85% | |||
| Return on Equity | -- | |||
| Income Statement | ALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 20.00K | |||
| Total Revenue (TTM) | 20.00K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | -82.21M | |||
| EBITDA (TTM) | -102.93M | |||
| EBIT (TTM) | -103.17M | |||
| Net Income (TTM) | -95.06M | |||
| Net Income Avl. to Common (TTM) | -95.06M | |||
| Total Revenue Growth (Q YOY) | -86.49% | |||
| Earnings Growth (Q YOY) | 26.74% | |||
| EPS Diluted (TTM) | -1.34 | |||
| EPS Diluted Growth (Q YOY) | 39.92% | |||
| Balance Sheet | ALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 131.89M | |||
| Cash Per Share (Q) | $1.85 | |||
| Total Current Assets (Q) | 137.25M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 123.51M | |||
| Current Ratio (Q) | 13.112 | |||
| Book Value Per Share (Q) | $1.71 | |||
| Total Assets (Q) | 139.31M | |||
| Total Current Liabilities (Q) | 10.47M | |||
| Total Debt (Q) | 1.68M | |||
| Total Liabilities (Q) | 15.80M | |||
| Total Common Equity (Q) | 123.51M | |||
| Cash Flow | ALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -28.39M | |||
| Cash from Financing (TTM) | 10.04M | |||
| Net Change in Cash (TTM) | -98.19M | |||
| Levered Free Cash Flow (TTM) | -44.87M | |||
| Cash from Operations (TTM) | -79.85M | |||
